oric
pharmaceuticals
announces
presentation
preclinical
data
glucocorticoid
receptor
antagonist
overcoming
resistance
androgen
receptor
degrader
symposium
south
san
francisco
san
diego
globe
newswire
oric
pharmaceuticals
nasdaq
oric
clinical
stage
oncology
company
focused
developing
treatments
address
mechanisms
therapeutic
resistance
today
announced
poster
presentation
oral
discussion
upcoming
symposium
molecular
targets
cancer
therapeutics
held
virtually
october
presentation
highlight
preclinical
data
prostate
cancer
cell
lines
demonstrate
company
glucocorticoid
receptor
gr
antagonist
reversing
resistance
androgen
receptor
ar
degrader
study
observed
upon
treatment
prostate
cancer
cell
lines
ar
degrader
gr
mrna
protein
levels
significantly
upregulated
similar
gr
upregulation
seen
dosing
enzalutamide
gr
upregulation
translated
gr
activation
conferred
resistance
ar
degrader
permitting
prostate
cancer
cells
continue
grow
shown
completely
reverse
effects
block
tumor
cell
growth
gene
expression
data
demonstrate
gr
may
mechanism
resistance
ar
degraders
vitro
overcomes
resistance
ar
degradation
gr
linked
resistance
multiple
classes
cancer
therapeutics
across
variety
solid
tumors
currently
two
separate
phase
trials
combination
xtandi
enzalutamide
metastatic
prostate
cancer
abraxane
advanced
metastatic
solid
tumors
oric
expects
report
interim
data
one
trials
first
half
trial
second
half
details
poster
presentation
follows
title
overcomes
resistance
ar
degradation
prostate
cancer
models
date
october
cest
session
poster
discussion
session
topic
approaches
overcoming
therapeutic
resistance
abstract
oric
pharmaceuticals
oric
pharmaceuticals
clinical
stage
biopharmaceutical
company
dedicated
improving
patients
lives
overcoming
resistance
cancer
oric
lead
product
candidate
potent
selective
small
molecule
antagonist
glucocorticoid
receptor
linked
resistance
multiple
classes
cancer
therapeutics
across
variety
solid
tumors
currently
two
separate
phase
trials
combination
xtandi
enzalutamide
metastatic
prostate
cancer
abraxane
advanced
metastatic
solid
tumors
oric
product
candidates
include
orally
bioavailable
small
molecule
inhibitor
key
node
adenosine
pathway
believed
play
central
role
resistance
treatment
regimens
allosteric
inhibitor
polycomb
repressive
complex
via
eed
subunit
developed
prostate
cancer
beyond
three
product
candidates
oric
also
developing
multiple
precision
medicines
targeting
hallmark
cancer
resistance
mechanisms
oric
offices
south
san
francisco
san
diego
california
information
please
go
cautionary
note
regarding
statements
press
release
contains
statements
oric
term
defined
section
securities
act
section
securities
exchange
act
statements
press
release
purely
historical
statements
statements
include
among
things
statements
regarding
oric
development
plans
ability
overcome
resistance
cancer
models
plans
underlying
clinical
trials
development
plans
report
interim
data
two
ongoing
clinical
trials
potential
advantages
oric
product
candidates
words
believes
anticipates
plans
expects
intends
goal
potential
similar
expressions
intended
identify
statements
statements
contained
herein
based
upon
oric
current
expectations
involve
assumptions
may
never
materialize
may
prove
incorrect
actual
results
could
differ
materially
projected
statements
due
numerous
risks
uncertainties
including
limited
risks
associated
process
discovering
developing
commercializing
drugs
safe
effective
use
human
therapeutics
operating
early
clinical
stage
company
oric
ability
develop
initiate
complete
preclinical
studies
clinical
trials
obtain
approvals
commercialize
product
candidates
changes
oric
plans
develop
commercialize
product
candidates
potential
clinical
trials
future
clinical
trials
product
candidates
differ
preclinical
preliminary
expected
results
negative
impacts
pandemic
oric
operations
including
clinical
trials
oric
ability
raise
additional
funding
need
continue
pursue
business
product
development
plans
regulatory
developments
united
states
foreign
countries
oric
reliance
third
parties
including
contract
manufacturers
contract
research
organizations
oric
ability
obtain
maintain
intellectual
property
protection
product
candidates
loss
key
scientific
management
personnel
competition
industry
oric
operates
general
economic
market
conditions
risks
information
regarding
foregoing
additional
risks
may
found
section
entitled
risk
factors
oric
quarterly
report
form
filed
securities
exchange
commission
sec
august
oric
future
reports
filed
sec
statements
made
date
press
release
oric
assumes
obligation
update
statements
update
reasons
actual
results
could
differ
projected
statements
except
required
law
contact
dominic
piscitelli
chief
financial
officer
info
